MA31683B1 - Composes et procedes pour moduler fxr - Google Patents
Composes et procedes pour moduler fxrInfo
- Publication number
- MA31683B1 MA31683B1 MA32615A MA32615A MA31683B1 MA 31683 B1 MA31683 B1 MA 31683B1 MA 32615 A MA32615 A MA 32615A MA 32615 A MA32615 A MA 32615A MA 31683 B1 MA31683 B1 MA 31683B1
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- modulation components
- fxr modulation
- fxr
- dyslipidemia
- Prior art date
Links
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 2
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94997407P | 2007-07-16 | 2007-07-16 | |
| PCT/US2008/069719 WO2009012125A1 (en) | 2007-07-16 | 2008-07-11 | Compounds and methods for modulating fxr |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA31683B1 true MA31683B1 (fr) | 2010-09-01 |
Family
ID=39855171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA32615A MA31683B1 (fr) | 2007-07-16 | 2010-02-11 | Composes et procedes pour moduler fxr |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8153624B2 (Direct) |
| EP (1) | EP2178851B1 (Direct) |
| JP (1) | JP5373788B2 (Direct) |
| KR (1) | KR101157334B1 (Direct) |
| CN (1) | CN101743232B (Direct) |
| AR (1) | AR067540A1 (Direct) |
| AT (1) | ATE539065T1 (Direct) |
| AU (1) | AU2008276236B2 (Direct) |
| BR (1) | BRPI0814571A2 (Direct) |
| CA (1) | CA2693406C (Direct) |
| CL (1) | CL2008002051A1 (Direct) |
| CO (1) | CO6270212A2 (Direct) |
| CY (1) | CY1112298T1 (Direct) |
| DK (1) | DK2178851T3 (Direct) |
| DO (1) | DOP2010000018A (Direct) |
| EA (1) | EA016475B1 (Direct) |
| EC (1) | ECSP109879A (Direct) |
| ES (1) | ES2376176T3 (Direct) |
| HR (1) | HRP20120048T1 (Direct) |
| IL (1) | IL202234A0 (Direct) |
| MA (1) | MA31683B1 (Direct) |
| MX (1) | MX2010000502A (Direct) |
| PE (1) | PE20090809A1 (Direct) |
| PL (1) | PL2178851T3 (Direct) |
| PT (1) | PT2178851E (Direct) |
| RS (1) | RS52216B (Direct) |
| SI (1) | SI2178851T1 (Direct) |
| SV (1) | SV2010003458A (Direct) |
| TN (1) | TN2010000028A1 (Direct) |
| TW (1) | TW200906823A (Direct) |
| WO (1) | WO2009012125A1 (Direct) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2289883A1 (en) * | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| CU24152B1 (es) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| EP2655369A1 (en) * | 2010-12-20 | 2013-10-30 | Irm Llc | Compositions and methods for modulating farnesoid x receptors |
| US20130261108A1 (en) * | 2010-12-20 | 2013-10-03 | Irm Llc | Compositions and methods for modulating farnesoid x receptors |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| WO2013037482A1 (en) | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| EP2970177A1 (en) | 2013-03-15 | 2016-01-20 | Pfizer Inc. | Indole compounds that activate ampk |
| MY186752A (en) | 2013-09-11 | 2021-08-18 | Inst Nat Sante Rech Med | Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection |
| PE20160682A1 (es) | 2013-11-05 | 2016-07-23 | Novartis Ag | Composiciones y metodos para modular los receptores x farnesoides |
| CN104045635A (zh) * | 2014-06-23 | 2014-09-17 | 华东理工大学 | 3,4,5-三取代异恶唑类化合物及其用途 |
| EP3006939A1 (en) | 2014-10-06 | 2016-04-13 | Gilead Sciences, Inc. | Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| EP3034499A1 (en) * | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Novel FXR (NR1H4) modulating compounds |
| EP3034501A1 (en) * | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Hydroxy containing FXR (NR1H4) modulating compounds |
| US11311557B2 (en) | 2015-02-06 | 2022-04-26 | Intercept Pharmaceuticals, Inc. | Pharmaceutical compositions for combination therapy |
| TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
| SMT202100593T1 (it) | 2015-03-31 | 2021-11-12 | Enanta Pharm Inc | Derivati degli acidi biliari come agonisti di fxr/tgr5 e metodi per il loro uso |
| CA2981507A1 (en) | 2015-04-07 | 2016-10-13 | Intercept Pharmaceuticals, Inc. | Pharmaceutical compositions for combination therapy |
| CN106946867B (zh) * | 2016-01-06 | 2019-11-12 | 广州市恒诺康医药科技有限公司 | Fxr受体调节剂及其制备方法和用途 |
| CN107021958A (zh) * | 2016-02-01 | 2017-08-08 | 山东轩竹医药科技有限公司 | Fxr受体激动剂 |
| UA124499C2 (uk) | 2016-03-28 | 2021-09-29 | Інтерсепт Фармасьютікалз, Інк. | Лікарський препарат, одержаний шляхом комбінування агоніста fxr i arb |
| US10080742B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| WO2017189663A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| US10080741B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| US10149835B2 (en) | 2016-05-18 | 2018-12-11 | Elmore Patent Law Group, P.C. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| US10144729B2 (en) | 2016-05-18 | 2018-12-04 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
| US10138228B2 (en) | 2016-05-18 | 2018-11-27 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use therof |
| BR112018075734A2 (pt) | 2016-06-13 | 2019-04-02 | Gilead Sciences, Inc. | composto, composição farmacêutica, método para tratar um paciente com uma doença ou condição mediada pelo menos em parte por fxr, e, uso de um composto. |
| CA3252823A1 (en) | 2016-06-13 | 2025-02-25 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
| TW201808283A (zh) | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | 含氮三環化合物及其在藥物中的應用 |
| EP3954684A1 (en) | 2016-08-23 | 2022-02-16 | Ardelyx, Inc. | Process for the preparation of hormone receptor modulators for treating metabolic conditions and disorders |
| WO2018039384A1 (en) | 2016-08-23 | 2018-03-01 | Ardelyx, Inc. | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as fxr activators |
| EP3512514A1 (en) * | 2016-09-14 | 2019-07-24 | Novartis AG | Novel regimes of fxr agonists |
| BR112019006651A2 (pt) * | 2016-10-04 | 2019-07-02 | Enanta Pharm Inc | análogos de isoxazol como agonistas de fxr e métodos de uso do mesmo |
| US10597391B2 (en) | 2016-10-26 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof |
| CN108017636A (zh) | 2016-11-04 | 2018-05-11 | 合帕吉恩治疗公司 | 作为fxr调节剂的含氮杂环化合物 |
| CN108218852A (zh) * | 2016-12-15 | 2018-06-29 | 宁波百纳西药业有限公司 | 一种螺环化合物、其制备方法、组合物及用途 |
| JP6906626B2 (ja) | 2017-03-28 | 2021-07-21 | ギリアード サイエンシーズ， インコーポレイテッド | 肝疾患を処置するための治療的組み合わせ |
| US20210085662A1 (en) | 2017-03-30 | 2021-03-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses |
| KR102168543B1 (ko) | 2017-04-12 | 2020-10-21 | 일동제약(주) | 핵 수용체의 효능제인 아이속사졸 유도체 및 이의 용도 |
| CN109265471B (zh) * | 2017-06-30 | 2021-06-04 | 轩竹生物科技有限公司 | Fxr受体激动剂 |
| CN109320509B (zh) * | 2017-07-31 | 2022-02-08 | 轩竹生物科技股份有限公司 | Fxr受体激动剂 |
| CN111655680B (zh) | 2017-09-14 | 2024-03-05 | 阿德利克斯股份有限公司 | 用于治疗代谢突变和纤维化病状及病症的激素受体调节剂 |
| JP7212693B2 (ja) | 2017-11-01 | 2023-01-25 | ブリストル－マイヤーズ スクイブ カンパニー | ファルネソイドｘ受容体モジュレーターとしての架橋二環化合物 |
| TW201922737A (zh) | 2017-11-01 | 2019-06-16 | 美商必治妥美雅史谷比公司 | 作為法尼醇x受體調節劑之螺環化合物 |
| ES2944601T3 (es) | 2017-11-01 | 2023-06-22 | Bristol Myers Squibb Co | Compuestos multicíclicos como moduladores del receptor farnesoide X |
| EP3704106B1 (en) * | 2017-11-01 | 2023-04-12 | Bristol-Myers Squibb Company | Alkene compounds as farnesoid x receptor modulators |
| US11286252B2 (en) | 2017-11-01 | 2022-03-29 | Bristol-Myers Squibb Company | Alkene spirocyclic compounds as farnesoid X receptor modulators |
| US10689391B2 (en) | 2017-12-12 | 2020-06-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
| KR20200102415A (ko) | 2017-12-22 | 2020-08-31 | 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 | 이소옥사졸 유도체, 그 제조 방법 및 그 용도 |
| CN110128432B (zh) | 2018-02-02 | 2021-03-02 | 广东东阳光药业有限公司 | 含氮三环化合物及其在药物中的应用 |
| US10829486B2 (en) | 2018-02-14 | 2020-11-10 | Enanta Pharmacueticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| CN110452235B (zh) * | 2018-05-08 | 2023-02-17 | 中国科学院上海药物研究所 | 一类含氟异噁唑类化合物及其制备方法、药物组合物和用途 |
| WO2020042114A1 (en) * | 2018-08-30 | 2020-03-05 | Terns Pharmaceuticals, Inc. | Treating liver disorders |
| CN111320609A (zh) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| EA202191566A1 (ru) | 2019-01-15 | 2021-11-01 | Джилид Сайенсиз, Инк. | Соединения, модулирующие fxr (nr1h4) |
| US12479816B2 (en) | 2019-02-08 | 2025-11-25 | University of Pittsburgh—of the Commonwealth System of Higher Education | 20-HETE formation inhibitors |
| CA3129619A1 (en) | 2019-02-15 | 2020-08-20 | Bristol-Myers Squibb Company | Substituted amide compounds useful as farnesoid x receptor modulators |
| JP7449300B2 (ja) | 2019-02-15 | 2024-03-13 | ブリストル－マイヤーズ スクイブ カンパニー | ファルネソイドｘ受容体モジュレータとして有用な置換アミド化合物 |
| AR118050A1 (es) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x |
| EA202192275A1 (ru) | 2019-02-15 | 2021-11-03 | Бристол-Маерс Сквибб Компани | Замещенные амидные соединения, полезные в качестве модуляторов фарнезоидного x-рецептора |
| CN118388473A (zh) | 2019-02-19 | 2024-07-26 | 吉利德科学公司 | Fxr激动剂的固体形式 |
| US12240841B2 (en) | 2019-04-19 | 2025-03-04 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | FXR small molecule agonist and preparation method therefor and use thereof |
| WO2020231917A1 (en) * | 2019-05-13 | 2020-11-19 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| CA3142358A1 (en) | 2019-05-30 | 2020-12-03 | Intercept Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease |
| AU2020312735A1 (en) | 2019-07-18 | 2021-12-16 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
| CA3154391A1 (en) | 2019-09-12 | 2021-03-18 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| IL292459A (en) * | 2019-11-08 | 2022-06-01 | Terns Pharmaceuticals Inc | Treatment of liver disorders |
| WO2021108974A1 (en) | 2019-12-03 | 2021-06-10 | Gannex Pharma Co., Ltd | Compounds for modulating activity of fxr and uses thereof |
| JP2023510274A (ja) | 2020-01-15 | 2023-03-13 | アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） | Ｄ型肝炎ウイルスによる感染を処置するためのｆｘｒアゴニストの使用 |
| CN115811972A (zh) * | 2020-05-13 | 2023-03-17 | 拓臻制药公司 | 肝脏病症的组合治疗 |
| KR20230058112A (ko) | 2020-08-25 | 2023-05-02 | 일라이 릴리 앤드 캄파니 | Ssao 억제제의 다형체 |
| WO2022056238A1 (en) * | 2020-09-11 | 2022-03-17 | Terns Pharmaceuticals, Inc. | Solid dispersion formulations of an fxr agonist |
| US20220135540A1 (en) * | 2020-10-15 | 2022-05-05 | Eli Lilly And Company | Polymorphs of an fxr agonist |
| JP2024502673A (ja) | 2021-01-14 | 2024-01-22 | ウエヌイグレックオ・ファーマ | Ｈｂｖ感染の処置のためのｆｘｒアゴニストとｉｆｎの相乗効果 |
| US20240216364A1 (en) | 2021-04-28 | 2024-07-04 | Enyo Pharma | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment |
| CA3238082A1 (en) | 2021-11-11 | 2023-05-19 | Terns Pharmaceuticals, Inc. | Combination of a ssao inhibitor and thr-beta agonist for use in the treatment of liver disorders |
| WO2023220404A1 (en) * | 2022-05-13 | 2023-11-16 | Terns Pharmaceuticals, Inc. | Treatment of non-alcoholic steatohepatitis |
| CN115850152B (zh) * | 2022-12-20 | 2025-10-31 | 河北鼎泰制药有限公司 | 一种杂质A-7-imp3的制备方法及其用途 |
| TW202506131A (zh) | 2023-04-07 | 2025-02-16 | 美商拓臻製藥公司 | ＧＬＰ－１Ｒ及ＴＨＲβ激動劑之組合以及其使用方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07138258A (ja) * | 1993-11-16 | 1995-05-30 | Taiho Yakuhin Kogyo Kk | チアゾリジンジオン誘導体又はその塩 |
| WO2000037077A1 (en) | 1998-12-23 | 2000-06-29 | Glaxo Group Limited | Assays for ligands for nuclear receptors |
| US6967212B2 (en) * | 2001-05-30 | 2005-11-22 | Bristol-Myers Squibb Company | Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method |
| US7105556B2 (en) * | 2001-05-30 | 2006-09-12 | Bristol-Myers Squibb Company | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
| DE60131967D1 (de) | 2001-08-13 | 2008-01-31 | Phenex Pharmaceuticals Ag | Nr1h4-kern-rezeptor-bindende verbindungen |
| WO2004004655A2 (en) | 2002-07-09 | 2004-01-15 | Bristol-Myers Squibb Company | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
| US7319109B2 (en) | 2002-11-22 | 2008-01-15 | Smith Kline Beecham Corporation | Farnesoid X receptor agonists |
| ES2452031T3 (es) * | 2006-02-03 | 2014-03-31 | Eli Lilly & Company | Compuestos y procedimientos para modular receptores FX |
| AU2007267692B2 (en) | 2006-05-24 | 2012-06-14 | Eli Lilly And Company | Compounds and methods for modulating FXR |
| MX2008014854A (es) | 2006-05-24 | 2008-12-05 | Lilly Co Eli | Antagonistas de fxr. |
-
2008
- 2008-07-03 TW TW097125064A patent/TW200906823A/zh unknown
- 2008-07-11 US US12/600,879 patent/US8153624B2/en active Active
- 2008-07-11 RS RS20120099A patent/RS52216B/sr unknown
- 2008-07-11 ES ES08781651T patent/ES2376176T3/es active Active
- 2008-07-11 WO PCT/US2008/069719 patent/WO2009012125A1/en not_active Ceased
- 2008-07-11 KR KR1020107000896A patent/KR101157334B1/ko not_active Expired - Fee Related
- 2008-07-11 CA CA2693406A patent/CA2693406C/en not_active Expired - Fee Related
- 2008-07-11 AT AT08781651T patent/ATE539065T1/de active
- 2008-07-11 SI SI200830514T patent/SI2178851T1/sl unknown
- 2008-07-11 MX MX2010000502A patent/MX2010000502A/es active IP Right Grant
- 2008-07-11 EP EP08781651A patent/EP2178851B1/en active Active
- 2008-07-11 CN CN2008800247651A patent/CN101743232B/zh active Active
- 2008-07-11 PT PT08781651T patent/PT2178851E/pt unknown
- 2008-07-11 HR HR20120048T patent/HRP20120048T1/hr unknown
- 2008-07-11 PE PE2008001168A patent/PE20090809A1/es not_active Application Discontinuation
- 2008-07-11 EA EA201070148A patent/EA016475B1/ru not_active IP Right Cessation
- 2008-07-11 PL PL08781651T patent/PL2178851T3/pl unknown
- 2008-07-11 JP JP2010517082A patent/JP5373788B2/ja active Active
- 2008-07-11 DK DK08781651.8T patent/DK2178851T3/da active
- 2008-07-11 BR BRPI0814571-7A2A patent/BRPI0814571A2/pt not_active IP Right Cessation
- 2008-07-11 AU AU2008276236A patent/AU2008276236B2/en not_active Ceased
- 2008-07-14 AR ARP080103026A patent/AR067540A1/es not_active Application Discontinuation
- 2008-07-14 CL CL2008002051A patent/CL2008002051A1/es unknown
-
2009
- 2009-11-19 IL IL202234A patent/IL202234A0/en unknown
-
2010
- 2010-01-12 CO CO10002335A patent/CO6270212A2/es not_active Application Discontinuation
- 2010-01-12 DO DO2010000018A patent/DOP2010000018A/es unknown
- 2010-01-15 EC EC2010009879A patent/ECSP109879A/es unknown
- 2010-01-15 TN TNP2010000028A patent/TN2010000028A1/fr unknown
- 2010-01-15 SV SV2010003458A patent/SV2010003458A/es not_active Application Discontinuation
- 2010-02-11 MA MA32615A patent/MA31683B1/fr unknown
-
2012
- 2012-01-27 CY CY20121100098T patent/CY1112298T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA31683B1 (fr) | Composes et procedes pour moduler fxr | |
| MA29377B1 (fr) | Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif | |
| MA64509B1 (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
| WO2019035863A8 (en) | PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS | |
| MA64121B1 (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
| MA31906B1 (fr) | Inhibiteurs de la replication du virus de limmunodeficience humaine | |
| MA32729B1 (fr) | Derives d'acide 1-amino-2-cyclobutylethylboronique | |
| MA33419B1 (fr) | Composés et compositions pour le traitement de maladies parasitaires | |
| MA30427B1 (fr) | Derives bicycliques utilises comme inhibiteurs de cetp | |
| MA29785B1 (fr) | Agents permettant de prevenir et de traiter des troubles entrainant la modulation des recepteurs ryr | |
| MA35036B1 (fr) | Composés bis(fluoroalkyl)-1,4-benzodiazépinone | |
| MA32134B1 (fr) | Composés hétérocycliques | |
| TN2009000450A1 (fr) | Derives de pyridine | |
| MA31764B1 (fr) | Composés et compositions en tant que modulateurs de l'activité de gpr119 | |
| MA31952B1 (fr) | Pyrrolopyrimidines et pyrrolopyridines | |
| MA29568B1 (fr) | Composes d'azaindazole et methodes d'utilisation desdits composes | |
| MA42410A (fr) | Oxystérols et leurs méthodes d'utilisation | |
| MA29909B1 (fr) | Derives de pyridazine | |
| EA200900828A1 (ru) | Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1 | |
| MA31766B1 (fr) | Composés organiques | |
| MA38391B1 (fr) | Dérivés de pyridinyl et triazolone pyridinyl de fusion | |
| MA30717B1 (fr) | Derives de pyridin-3-yle en tant qu'agents immunomodulateurs | |
| MA30718B1 (fr) | Derives de pyridin-4-yle en tant qu'agents immunomodulateurs. | |
| MA31754B1 (fr) | Cis-imidazolines chirales | |
| MA32466B1 (fr) | Derives de triazole utiles pour le traitement de maladies |